122 related articles for article (PubMed ID: 11127395)
1. Childhood all blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice.
Borgmann A; Baldy C; von Stackelberg A; Beyermann B; Fichtner I; Nürnberg P; Henze G
Pediatr Hematol Oncol; 2000 Dec; 17(8):635-50. PubMed ID: 11127395
[TBL] [Abstract][Full Text] [Related]
2. Elimination of leukemia in the absence of lethal graft-versus-host disease after allogenic bone marrow transplantation.
Drobyski WR; Gendelman M; Vodanovic-Jankovic S; Gorski J
J Immunol; 2003 Mar; 170(6):3046-53. PubMed ID: 12626559
[TBL] [Abstract][Full Text] [Related]
3. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
4. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
5. Manipulation of graft-versus-host disease for a graft-versus-leukemia effect after allogeneic bone marrow transplantation in AKR mice with spontaneous leukemia/lymphoma.
Truitt RL; Shih CC; LeFever AV
Transplantation; 1986 Mar; 41(3):301-10. PubMed ID: 3513389
[TBL] [Abstract][Full Text] [Related]
6. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
7. Generation of alloreactive anti-leukemic cytotoxic T lymphocytes with attenuated GVHD properties from haploidentical parents in childhood acute lymphoblastic leukemia.
Jurickova I; Waller EK; Yeager AM; Boyer MW
Bone Marrow Transplant; 2002 Nov; 30(10):687-97. PubMed ID: 12420208
[TBL] [Abstract][Full Text] [Related]
8. CD34+ cord blood DC-induced antitumor lymphoid cells have efficacy in a murine xenograft model of human ALL.
Cullup H; Hsu AK; Kassianos AJ; McDonald K; Radford KJ; Rice AM
J Immunother; 2011 May; 34(4):362-71. PubMed ID: 21499125
[TBL] [Abstract][Full Text] [Related]
9. Human allo-reactive CD4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia.
Stevanović S; Griffioen M; Nijmeijer BA; van Schie ML; Stumpf AN; Rutten CE; Willemze R; Falkenburg JH
Leukemia; 2012 Feb; 26(2):312-22. PubMed ID: 21860431
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
11. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
Xun CQ; Thompson JS; Jennings CD; Brown SA
Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
[TBL] [Abstract][Full Text] [Related]
12. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?
Slavin S; Ackerstein A; Naparstek E; Or R; Weiss L
Bone Marrow Transplant; 1990 Sep; 6(3):155-61. PubMed ID: 2252954
[TBL] [Abstract][Full Text] [Related]
13. An animal model for human cellular immunotherapy: specific eradication of human acute lymphoblastic leukemia by cytotoxic T lymphocytes in NOD/scid mice.
Nijmeijer BA; Willemze R; Falkenburg JH
Blood; 2002 Jul; 100(2):654-60. PubMed ID: 12091361
[TBL] [Abstract][Full Text] [Related]
14. Good engraftment of B-cell precursor ALL in NOD-SCID mice.
Baersch G; Möllers T; Hötte A; Dockhorn-Dworniczak B; Rübe C; Ritter J; Jürgens H; Vormoor J
Klin Padiatr; 1997; 209(4):178-85. PubMed ID: 9293448
[TBL] [Abstract][Full Text] [Related]
15. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties.
le Viseur C; Hotfilder M; Bomken S; Wilson K; Röttgers S; Schrauder A; Rosemann A; Irving J; Stam RW; Shultz LD; Harbott J; Jürgens H; Schrappe M; Pieters R; Vormoor J
Cancer Cell; 2008 Jul; 14(1):47-58. PubMed ID: 18598943
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia.
Cox CV; Martin HM; Kearns PR; Virgo P; Evely RS; Blair A
Blood; 2007 Jan; 109(2):674-82. PubMed ID: 17003368
[TBL] [Abstract][Full Text] [Related]
17. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.
Hill GR; Teshima T; Gerbitz A; Pan L; Cooke KR; Brinson YS; Crawford JM; Ferrara JL
J Clin Invest; 1999 Aug; 104(4):459-67. PubMed ID: 10449438
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.
Vourka-Karussis U; Ackerstein A; Pugatsch T; Slavin S
Exp Hematol; 1999 Mar; 27(3):461-9. PubMed ID: 10089908
[TBL] [Abstract][Full Text] [Related]
19. Strong increase in the percentage of the CD8bright+ CD28- T-cells and delayed engraftment associated with cyclosporine-induced autologous GVHD.
Garin L; Rigal D; Souillet G; Bernaud J; Mérieux Y; Philippe N
Eur J Haematol; 1996 Mar; 56(3):119-23. PubMed ID: 8598229
[TBL] [Abstract][Full Text] [Related]
20. In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities.
van Lochem E; de Gast B; Goulmy E
Bone Marrow Transplant; 1992 Aug; 10(2):181-3. PubMed ID: 1525608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
